Skip to main content

Table 1 Patients and tumours characteristics

From: BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer

   PARP activity (Low < 7 U / mg Protein, High ≥ 7 U / mg Protein) BRCA1methylation status
Patients’ characteristics N (%) Low n (%) High n (%) p Mean ± SD p Methylated n (%) Not Methylated n (%) p
Age at diagnosis (years)     0.92   0.83    0.17
Median (range) 54 (29–75)         
≤ 54 80 (51.6%) 38 (52.1%) 42 (51.2%)   11.7 (13)   12 (66.7%) 68 (49.6%)  
> 54 75 (48.4%) 35 (47.9%) 40 (48.8%)   12.7 (20.5)   6 (33.3%) 69 (50.4%)  
Menopausal status     0.87   0.54    0.62
Pre-menopausal 69 (44.5%) 33 (45.2%) 36 (43.9%)   12.5 (13.8)   9 (50.0%) 60 (43.8%)  
Post-menopausal 86 (55.5%) 40 (54.8%) 46 (56.1%)   11.9 (19.3)   9 (50.0%) 77 (56.2%)  
T classification     0.67   0.60    0.76
T1 76 (49%) 36 (49.3%) 40 (48.8%)   14 (21.1)   9 (50.0%) 67 (48.9%)  
T2 75 (48.4%) 36 (49.3%) 39 (47.6%)   10.4 (12)   9 (50.0%) 66 (48.2%)  
T3-4 4 (2.6%) 1 (1.4%) 3 (3.7%)   10 (3.7)   0 4 (2.9%)  
N classification     0.75   0.8    0.71
N0 106 (68.4%) 49 (67.1%) 57 (69.5%)   12.4 (18.1)   13 (72.2%) 93 (67.9%)  
N+ 49 (31.6%) 24 (32.9%) 25 (30.5%)   11.8 (14.6)   5 (27.8%) 44 (32.1%)  
Histology     0.27   0.3    0.53
Ductal 120 (77.4%) 53 (72.6%) 67 (81.7%)   13.1 (18.3)   15 (83.3%) 105 (76.6%)  
Lobular 9 (5.8%) 4 (5.5%) 5 (6.1%)   7.8 (8.3)   0 9 (6.6%)  
Other 26 (16.8%) 16 (21.9%) 10 (12.2%)   9.6 (12.5)   3 (16.7%) 23 (16.8%)  
Grade     0.23   0.02    0.03
I / II 1 (0.6%) / 51 (32.9%) 28 (38.4%) 24 (29.3%)   9.2 (12.8)   2 (11.1%) 50 (36.5%)  
III 103 (66.5%) 45 (61.6%) 58 (70.7%)   13.7 (18.7)   16 (88.9%) 87 (63.5%)  
Mitotic count score     0.04   0.003    0.04
1 31 (20%) 20 (27.4%) 11 (13.4%)   8.3 (13.6)   1 (5.6%) 30 (21.9%)  
2 62 (40%) 30 (41.1%) 32 (39.0%)   10.8 (16.2)   5 (27.8%) 57 (41.6%)  
3 62 (40%) 23 (31.5%) 39 (47.6%)   15.6 (18.8)   12 (66.7%) 50 (36.5%)  
ER     0.88   0.66    0.001
Positive 88 (56.8%) 41 (56.2%) 47 (57.3%)   12.1 (16.9)   4 (22.2%) 84 (61.3%)  
Negative 67 (43.2%) 32 (43.8%) 35 (42.7%)   12.4 (17.3)   14 (77.8%) 53 (38.7%)  
PR     0.94   0.75    0.01
Positive 59 (38.1%) 28 (38.4%) 31 (37.8%)   11.5 (14.3)   2 (11.1%) 57 (41.6%)  
Negative 96 (61.9%) 45 (61.6%) 51 (62.2%)   12.6 (18.6)   16 (88.9%) 80 (58.4%)  
HER2     0.62   0.5    0.01
Positive 50 (32.3%) 25 (34.2%) 25 (30.5%)   9.7 (11.3)   1 (5.6%) 49 (35.8%)  
Negative 105 (67.7%) 48 (65.8%) 57 (69.5%)   13.4 (19.1)   17 (94.4%) 88 (64.2%)  
Molecular profile grouping     0.81   0.68    <0.001
HER2+ 50 (32.3%) 25 (34.2%) 25 (30.5%)   9.7 (11.3)   1 (5.6%) 49 (35.8%)  
HR+/HER2- 57 (36.7%) 25 (34.2%) 32 (39.0%)   13.4 (19.9)   3 (16.7%) 54 (39.4%)  
Triple negative 48 (31%) 23 (31.5%) 25 (30.5%)   13.4 (18.3)   14 (77.8%) 34 (24.8%)  
uPA level ( ≥3)     0.37   0.3    0.01
High 97 (62.6%) 43 (58.9%) 54 (65.9%)   12.9 (17)   16 (88.9%) 81 (59.1%)  
Low 58 (37.4%) 30 (41.1%) 28 (34.1%)   11 (17.2)   2 (11.1%) 56 (40.9%)  
PAI-1 level ( ≥14)     0.32   0.42    0.03
High 112 (72.3%) 50 (68.5%) 62 (75.6%)   11.4 (12.4)   17 (94.4%) 95 (69.3%)  
Low 43 (27.7%) 23 (31.5%) 20 (24.4%)   14.2 (25.5)   1 (5.6%) 42 (30.7%)  
PARP Activity          0.82
≤ 2.6 U/mg Prot 39 (25.2%) - - - - - 4 (22.2%) 35 (25.5%)  
2.7 - 7 42 (27.1%) - - - - - 6 (33.3%) 36 (26.3%)  
7.1 - 14 37 (23.9%) - - - - - 3 (16.7%) 34 (24.8%)  
> 14 37 (23.9%) - - - - - 5 (27.8%) 32 (23.4%)